UB Paderborn / Katalog / Suche / in CDI

1 – 18 von 18

Sortiert nach

DNA double-strand break repair pathways, chromosomal rearrangements and cancer

Seminars in cell & developmental biology, 2011-10, Vol.22 (8), p.886-897

2011

Volltextzugriff (PDF)

The DNA damage checkpoint pathway promotes extensive resection and nucleotide synthesis to facilitate homologous recombination repair and genome stability in fission yeast

Nucleic acids research, 2014-05, Vol.42 (9), p.5644

2014

Volltextzugriff (PDF)

The spliceosome-associated protein Nrl1 suppresses homologous recombination-dependent R-loop formation in fission yeast

Nucleic acids research, 2016-02, Vol.44 (4), p.1703

2016

Volltextzugriff (PDF)

42927 Unmet needs in treatment options and management strategies in hidradenitis suppurativa: understanding the patient perspective through social media listening

Journal of the American Academy of Dermatology, 2023-09, Vol.89 (3), p.AB102-AB102

2023

Volltextzugriff (PDF)

27476 Increased benefit of secukinumab vs ustekinumab in patients with psoriasis regardless of previous systemic psoriasis therapy: Pooled analysis of the phase 3 CLEAR and CLARITY trials

Journal of the American Academy of Dermatology, 2021-09, Vol.85 (3), p.AB147-AB147

2021

Volltextzugriff (PDF)

16317 Characterization of patient clusters based on response to treatment with secukinumab: A “pattern recognition” analysis of pooled phase 3 data

Journal of the American Academy of Dermatology, 2020-12, Vol.83 (6), p.AB60-AB60

2020

Volltextzugriff (PDF)

42652 Efficacy of secukinumab in patients with moderate-to-severe hidradenitis suppurativa previously treated with biologic therapy: Week 16 results from the SUNSHINE and SUNRISE trials

Journal of the American Academy of Dermatology, 2023-09, Vol.89 (3), p.AB160-AB160

2023

Volltextzugriff (PDF)

42981 Secukinumab and concomitant antibiotic use in patients with moderate-to-severe hidradenitis suppurativa: Week 16 eﬃcacy and safety results from the Phase 3 SUNSHINE and SUNRISE trials

Journal of the American Academy of Dermatology, 2023-09, Vol.89 (3), p.AB85-AB85

2023

Volltextzugriff (PDF)

Lower Limbs are the Most Difficult-to-Treat Body Region of Patients with Psoriasis: Pooled Analysis of CLEAR and CLARITY Studies of Secukinumab Versus Ustekinumab by Body Region

BioDrugs : clinical immunotherapeutics, biopharmaceuticals, and gene therapy, 2022-11, Vol.36 (6), p.781-789

2022

Volltextzugriff (PDF)

Understanding the real-world patient journey and unmet needs of people with hidradenitis suppurativa through social media research

British journal of dermatology (1951), 2023-07, Vol.189 (2), p.228-230

2023

Volltextzugriff (PDF)

25385 Secukinumab demonstrates high and sustained efficacy in nail psoriasis: Post hoc analyses from phase III studies in psoriasis and psoriatic arthritis (PsA)

Journal of the American Academy of Dermatology, 2021-09, Vol.85 (3), p.AB56-AB56

2021

Volltextzugriff (PDF)

Secukinumab demonstrates high and sustained efficacy in nail psoriasis: post hoc analysis from phase III trials in patients with psoriatic arthritis

British journal of dermatology (1951), 2022-09, Vol.187 (3), p.438-441

2022

Volltextzugriff (PDF)

Secukinumab versus guselkumab in the complete resolution of ustekinumab-resistant psoriatic plaques: The ARROW study

Experimental dermatology, 2023-10, Vol.32 (10), p.1834-1847

2023

Volltextzugriff (PDF)

Homologous recombination suppresses transgenerational DNA end resection and chromosomal instability in fission yeast

Nucleic acids research, 2023-04, Vol.51 (7), p.3205

2023

Volltextzugriff (PDF)

International Hidradenitis Suppurativa Severity Scoring System (IHS4) as a holistic measure of hidradenitis suppurativa disease severity compared with Hurley staging: A post hoc analysis of the SUNRISE and SUNSHINE phase 3 trials of secukinumab

Journal of the European Academy of Dermatology and Venereology, 2024-06, Vol.38 (6), p.e496

2024

Volltextzugriff (PDF)

Nail Involvement as a Predictor of Differential Treatment Effects of Secukinumab Versus Ustekinumab in Patients with Moderate to Severe Psoriasis

Dermatology and therapy, 2022-01, Vol.12 (1), p.233-241

2022

Volltextzugriff (PDF)

Impact of Psoriatic Disease on Quality of Life: Interim Results of a Global Survey

Dermatology and therapy, 2022-04, Vol.12 (4), p.1055-1064

2022

Volltextzugriff (PDF)

Identification and characterisation of determinants of genome stability in response to a double-strand break

Kasparek, Torben Rudolf

2013

Volltextzugriff (PDF)

1 – 18 von 18

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(17)
Mit Volltextzugriff
(13)

Publikationsform

Artikel
(17)
Dissertationen
(1)

Sprache

Englisch
(18)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

DNA double-strand break repair pathways, chromosomal rearrangements and cancer

The DNA damage checkpoint pathway promotes extensive resection and nucleotide synthesis to facilitate homologous recombination repair and genome stability in fission yeast

The spliceosome-associated protein Nrl1 suppresses homologous recombination-dependent R-loop formation in fission yeast

42927 Unmet needs in treatment options and management strategies in hidradenitis suppurativa: understanding the patient perspective through social media listening

27476 Increased benefit of secukinumab vs ustekinumab in patients with psoriasis regardless of previous systemic psoriasis therapy: Pooled analysis of the phase 3 CLEAR and CLARITY trials

16317 Characterization of patient clusters based on response to treatment with secukinumab: A “pattern recognition” analysis of pooled phase 3 data

42652 Efficacy of secukinumab in patients with moderate-to-severe hidradenitis suppurativa previously treated with biologic therapy: Week 16 results from the SUNSHINE and SUNRISE trials

42981 Secukinumab and concomitant antibiotic use in patients with moderate-to-severe hidradenitis suppurativa: Week 16 eﬃcacy and safety results from the Phase 3 SUNSHINE and SUNRISE trials

Lower Limbs are the Most Difficult-to-Treat Body Region of Patients with Psoriasis: Pooled Analysis of CLEAR and CLARITY Studies of Secukinumab Versus Ustekinumab by Body Region

Understanding the real-world patient journey and unmet needs of people with hidradenitis suppurativa through social media research

25385 Secukinumab demonstrates high and sustained efficacy in nail psoriasis: Post hoc analyses from phase III studies in psoriasis and psoriatic arthritis (PsA)

Secukinumab demonstrates high and sustained efficacy in nail psoriasis: post hoc analysis from phase III trials in patients with psoriatic arthritis

Secukinumab versus guselkumab in the complete resolution of ustekinumab-resistant psoriatic plaques: The ARROW study

Homologous recombination suppresses transgenerational DNA end resection and chromosomal instability in fission yeast

International Hidradenitis Suppurativa Severity Scoring System (IHS4) as a holistic measure of hidradenitis suppurativa disease severity compared with Hurley staging: A post hoc analysis of the SUNRISE and SUNSHINE phase 3 trials of secukinumab

Nail Involvement as a Predictor of Differential Treatment Effects of Secukinumab Versus Ustekinumab in Patients with Moderate to Severe Psoriasis

Impact of Psoriatic Disease on Quality of Life: Interim Results of a Global Survey

Identification and characterisation of determinants of genome stability in response to a double-strand break

Suchergebnisse filtern